NN6581 / Novo Nordisk - LARVOL DELTA

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Hepatology

Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Hepatology

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jan 2025 ➔ Aug 2025

Enrollment closed • Trial primary completion date • Hepatology

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Novo Nordisk A/S | N=32 ➔ 48

Enrollment change • Hepatology

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jan 2025 ➔ Nov 2025

Trial completion date • Hepatology

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Novo Nordisk A/S | N=48 ➔ 32

Enrollment change • Hepatology

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Hepatology